Kymera Therapeutics (NASDAQ:KYMR) Issues Quarterly Earnings Results

Kymera Therapeutics (NASDAQ:KYMR) posted its quarterly earnings results on Thursday. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.20), FiscalAI reports. The company had revenue of $2.87 million for the quarter, compared to analyst estimates of $14.80 million. Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%.The firm’s revenue for the quarter was down 60.8% compared to the same quarter last year. During the same period last year, the firm earned ($0.88) EPS.

Here are the key takeaways from Kymera Therapeutics’ conference call:

• Kymera’s first‑in‑class oral STAT6 degrader KT‑621 showed robust STAT6 degradation, strong type‑2 biomarker suppression and dupilumab‑like clinical signals in Phase 1/1b, and is now in Phase 2b trials for atopic dermatitis (enrollment expected complete end‑2026; topline mid‑2027) and asthma (first patient dosed; data expected late‑2027).
• Kymera has initiated dosing of its oral IRF5 degrader KT‑579 in a Phase 1 SAD/MAD healthy volunteer study after IND clearance and expects first‑in‑human data in H2 2026, with a planned lupus proof‑of‑concept to follow.
• The company raised nearly $1.0 billion in 2025 and finished the year with a cash balance of $1.6 billion, which management says provides a runway into 2029 to complete KT‑621 Phase 2b trials and advance KT‑579 and other programs.
• Kymera continues partnered development with Gilead (CDK2 molecular glue) and Sanofi (IRAK4 KT‑485), with potential milestone payments (Gilead up to ~$750M; Sanofi program structure could approach ~$1B) that aren’t included in current cash guidance.
• Q4 R&D expense was $83.8 million (cash R&D ~$76.2M), a 16% increase vs. Q3, highlighting rising development spend that will drive ongoing cash burn despite the stated runway.

Kymera Therapeutics Trading Up 4.8%

Shares of KYMR traded up $4.35 on Thursday, reaching $95.03. 1,396,717 shares of the company’s stock traded hands, compared to its average volume of 762,639. The stock’s 50 day simple moving average is $78.37 and its two-hundred day simple moving average is $64.89. The stock has a market cap of $6.84 billion, a PE ratio of -26.47 and a beta of 2.21. Kymera Therapeutics has a 52-week low of $19.44 and a 52-week high of $103.00.

Key Kymera Therapeutics News

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Piper Sandler raised its price target to $140 and reaffirmed an “overweight” rating, signaling strong analyst confidence and implying meaningful upside from current levels. Piper Sandler Raise
• Neutral Sentiment: BTIG trimmed its target slightly from $138 to $134 but kept a “buy” rating — a modest adjustment that maintains institutional support but is not a bearish signal. BTIG Note
• Negative Sentiment: Kymera reported Q4 EPS of ($0.97), missing consensus (loss of $0.77) and posted revenue of $2.87M versus estimates near $14.8M; revenue fell ~60.8% year‑over‑year — a material earnings and top-line miss that increases short-term execution risk. Q4 Results
• Negative Sentiment: CEO Nello Mainolfi sold 30,000 shares for ~$2.71M (filed with the SEC). Insider sales can be interpreted negatively by some investors even though the CEO retains a large stake. Insider Sale
• Neutral Sentiment: Technical/contextual note: the stock is trading well above its 50‑ and 200‑day moving averages and near its 52‑week high, reflecting strong momentum that may amplify both positive analyst headlines and headline-driven volatility.

Wall Street Analyst Weigh In

KYMR has been the topic of a number of research reports. Citigroup upped their price objective on Kymera Therapeutics from $80.00 to $110.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Stephens lifted their target price on Kymera Therapeutics from $65.00 to $110.00 and gave the company an “overweight” rating in a research report on Thursday, December 11th. Royal Bank Of Canada reiterated an “outperform” rating and set a $108.00 price target on shares of Kymera Therapeutics in a report on Thursday. UBS Group upgraded shares of Kymera Therapeutics to a “strong-buy” rating in a research report on Thursday, December 4th. Finally, Piper Sandler increased their price target on Kymera Therapeutics from $125.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $117.60.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 30,000 shares of the business’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $90.26, for a total value of $2,707,800.00. Following the sale, the chief executive officer directly owned 666,195 shares in the company, valued at $60,130,760.70. The trade was a 4.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jeffrey W. Albers sold 5,000 shares of the company’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $89.76, for a total transaction of $448,800.00. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 450,895 shares of company stock worth $40,486,151. 16.01% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD boosted its position in shares of Kymera Therapeutics by 20.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock valued at $479,258,000 after acquiring an additional 1,061,957 shares during the period. State Street Corp raised its holdings in shares of Kymera Therapeutics by 9.4% during the 4th quarter. State Street Corp now owns 2,209,837 shares of the company’s stock valued at $171,947,000 after buying an additional 190,383 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Kymera Therapeutics by 5.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 912,498 shares of the company’s stock worth $71,001,000 after buying an additional 48,736 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Kymera Therapeutics by 121.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock valued at $24,535,000 after acquiring an additional 491,737 shares during the last quarter. Finally, Federated Hermes Inc. raised its stake in shares of Kymera Therapeutics by 36.7% during the fourth quarter. Federated Hermes Inc. now owns 763,920 shares of the company’s stock worth $59,441,000 after acquiring an additional 205,220 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.